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Abstract 
We have developed an inter-agency referral and assessment process for children with behaviour problems.  ADHD is diagnosed 
using the DSM IV criteria (DSM IV, 1994).  During the period 1st June 2001 to 1st May 2008 303 children and young people 
with ADHD were entered on to the database.  We set out to compare two time lines: 1st May 2007 and 1st May 2008. On 1st May 
2007, 37.6% of patients were on LAMPH and 42.5% were on ATX. One year later 53.5% were on LAMPH and 17.5% were on 
ATX.  Methylphenidate continues to be the drug of choice in the management of ADHD.   
© 2010 Elsevier Ltd. 
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1. Introduction 
Over the past 70 years, doctors have used medication to help manage the core symptoms of ADHD.  The 
mainstay of treatment until 10 years ago was stimulant medication such as methylphenidate (MPH).  Non-stimulant 
medication has recently become more popular in the form of Atomoxetine (ATX) 
The National Institute for Clinical Excellence Guidelines (NICE, 2008) were published in 2008.  We set out to 
look at the situation in our clinic. 
We have the impression that the overriding factor in determining which medication the child or young person 
uses is parent and patient choice, rather then severity of symptoms. 
2. Methods 
The service for children with ADHD and Autistic Spectrum Disorder (ASD) on the Isle of Wight is described 
elsewhere (Rowlandson & Smith, 2009) 
Each child seen in ADHD clinic was added to a database.  We now have 303 patients on the ADHD database, with 
varying degree’s of severity of symptoms.  See tables 1 and 2. 
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Table 1.  Patient information
Males (n=258) Females (n=45) TOTAL 
Under 11 69 15 84ADHD diagnosis 
Over 11 98 13 111
Subtotal 167 28 195
Under 11 33 7 68ADHD+ASD diagnosis 
Over 11 58 10 40
Subtotal 91 17 108
TOTAL 258 45 303
Table 2.  Severity of symptoms
Males (n=258) Females (n=45) TOTAL 
Under 11 49 13 62Mild Symptoms* 
Over 11 49 11 60
Subtotal 98 24 122
Under 11 36 7 43Moderate 
Symptoms* Over 11 56 2 58
Subtotal 92 9 101
Under 11 20 2 22Severe
Symptoms* Over 11 48 10 58
Subtotal 68 12 80
TOTAL 258 45 303
*Severity characterised by: 
   Mild - ADHD symptoms do not lead to exclusion from school, or cause disruption to family life. 
  Moderate - Suffering impairment at school, and/or short term exclusion, family life difficult but not unbearable. 
  Severe - Facing permanent exclusion from school, and/or parents requesting respite care from social services. 
When choosing medication, our starting point is the NICE guidelines.  In moderate and severe cases, medication 
is recommended.    
In conjunction with drug treatment, we provide behavioural support and dietary advice. 
Outcomes are discussed in clinic in terms of attendance at school, academic performance, and we use the Dundee 
“difficult times of day” rating scale (Coghill, 2006) 
3. Results
It can be seen in figure 1 that a higher percentage of children were on medication in 2008 compared with 2007.  
The more striking difference was that the use of ATX had fallen from 53.5% to 17.5% in 2008 and  the use of 
LAMPH had risen from 37.6 % to 53.5%.  This was due to the fact that parents of children on ATX reported: no 
apparent effect at all (1/3) headaches or gastro-intestinal side effects (1/3), or emotional upset, excessively weepy 
and/or aggressive (1/3). 
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Graph 2. Prescribed medication differences in males and females, in 2008 
With regard to severity, those patients presenting with more severe symptoms, are more likely to be prescribed 
AMPH or a combination of LAMPH and RISP (see figure 3) 
tomoxetine is prescribed more commonly in those with mild symptoms. 
(Legend: in the following graphs percentage of children is on the vertical axis, medication on the horizontal axis. SAMPH: short acting 
methylphenidate; LAMPH long acting methylphenidate; ATX atomoxetine; RISP risperidone; MEL melatonin.) 
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Figure 1.  Medications prescribed in 2007 and 2008 (many children were on a combination of the above medications) 
There were a higher percentage of males than females on medication (see figure 2).  The striking difference was 
that females seemed to respond better to ATX than males. 
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Figure 3.  Prescribed medication compared to severity of symptoms 
The outcome data suggests that the severity of symptoms improved in approximately 70% of males and 62% of 
females on medication (figure 4).  Symptoms were monitored in regular clinic attendance. 
Figure 4.  Behaviour change following medication 
4. Discussion
In a condition such as ADHD adherence to medication is clearly going to depend 100% on the child and their 
parents, not only understanding, but agreeing with the rationale for medication, the therapeutic expectations and the 
possible side effects. 
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A very high proportion of parents will have heard of methylphenidate and will be aware of concerns expressed in 
the popular press.  When offered an alternative (ATX) which claims to work throughout the 24 hours, has an 
excellent side effect profile, and which is taken only once a day, many parents would opt for that medication; even 
allowing for the fact that it may take up to 6 weeks to have an effect. However, in real life 59% of those children 
who had started on ATX were withdrawn from the medication, due to lack of efficacy or side effects. 
A greater number of males were prescribed risperidone than females. The main indication for starting risperidone 
in our clinic is anxiety and aggression; it is not used to treat the core symptoms of ADHD.  Risperidone is therefore 
used more commonly in children with a co-morbid diagnosis of ADHD and ASD.  Some of the side effects of 
methylphenidate are ameliorated by the addition of risperidone.  The beneficial effects and side effects of these 
medications become apparent very rapidly.  Fine-tuning of the medication is therefore easier 
A similar amount of Melatonin was prescribed for both genders. It was very effective in the majority of patients 
and we experienced almost no side effects. 
5. Summary 
In real life the decision to start medication and which medication, is largely based on parent choice.  In our clinic, 
methylphenidate is the mainstay of treatment. Atomoxetine is a very useful drug, but not in the majority of cases.
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